<DOC>
	<DOCNO>NCT01360112</DOCNO>
	<brief_summary>A vaccine interrupt malaria transmission critical tool achieve ultimate goal eradication disease . Transmission block vaccine work induce antibody vaccinated individual inhibits development malaria parasite mosquito , thus interrupt cycle transmission next human host . Efficacy vaccine may estimate vitro membrane feeding assay use immune serum laboratory strain mosquito , assay need qualified determine extent predictive transmission block field . Clinical trial transmission block vaccine also anticipate start community . This protocol use nest casecontrol cohort design compare result mosquito feed assay malaria expose population Bancoumana surround village Mali . Households identify use census data individual consent participation . Malaria smear obtain monthly visit , gametocytemic individual ask participate direct feed experiment use insectary-raised mosquito . Infectivity mosquito compare mosquito feed membrane feeding assay Mali USA . Data also obtain gametocyte parasite carriage rate year . A total 250 volunteer Bancoumana , age 3 month 50 year , initially enrolled 2011 . In 2012 , additional 250 adult Bancoumana enrol participant old 5 year age enrol 2011 want continue participation re-enrolled study . A transmission block vaccine trial start May 2013 , enrol participant adult cohort study . Up 50 new adult Bancoumana surround village enrol 2014 volunteer previously enrol study theage 5 year old offer re-enrollment study .</brief_summary>
	<brief_title>Preventing Spread Malaria Mali</brief_title>
	<detailed_description>A vaccine interrupt malaria transmission critical tool achieve ultimate goal eradication disease . Transmission block vaccine work induce antibody vaccinated individual inhibits development malaria parasite mosquito , thus interrupt cycle transmission next human host . Efficacy vaccine may estimate vitro membrane feeding assay use immune serum laboratory strain mosquito , assay need qualified determine extent predictive transmission block field . Clinical trial transmission block vaccine also anticipate start community . This protocol use nest casecontrol cohort design compare result mosquito feed assay malaria expose population Bancoumana surround village Mali . Households identify use census data individual consent participation . Malaria smear obtain monthly visit , gametocytemic individual ask participate direct feed experiment use insectary-raised mosquito . Infectivity mosquito compare mosquito feed membrane feeding assay Mali USA . Data also obtain gametocyte parasite carriage rate year . A total 250 volunteer Bancoumana , age 3 month 50 year , initially enrolled 2011 . In 2012 , additional 250 adult Bancoumana enrol participant old 5 year age enrol 2011 want continue participation re-enrolled study . A transmission block vaccine trial start May 2013 , enrol participant adult cohort study . Up 50 new adult Bancoumana surround village enrol 2014 volunteer previously enrol study theage 5 year old offer re-enrollment study .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>INCLUSION CRITERIA : All follow criterion must fulfil volunteer participate study : 1 . Age 3 month 50 year , inclusive 2 . Good general health result review medical history and/or clinical testing time screen 3 . Available duration study ( 1 year ) 4 . Willingness participate study evidence sign informed consent document , fingerprint consent document signature witness 5 . Known resident village study 6 . Willingness allow store laboratory specimen use future research . 7 . In addition criterion , expand adult cohort must willing consider participation future malaria vaccine trial . EXCLUSION CRITERIA : A volunteer exclude participate study one follow criterion fulfil : 1 . Pregnancy determine history positive urine BetahCG test point study . 2 . Behavioral , cognitive , psychiatric disease opinion investigator affect ability subject understand cooperate study protocol . 3 . Other condition , opinion investigator , would jeopardize safety right volunteer participate trial would render subject unable comply protocol . 4 . Participation another investigational vaccine drug trial study ongoing . 5 . Previous receipt experimental malaria vaccine . 6 . Baseline hemoglobin &lt; 8.5 g/dL In addition criterion , volunteer exclude participate transmission block assay part study follow criterion fulfil : 7 . History reaction mosquito bite severe itch swelling , last long 3 day</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 3, 2016</verification_date>
	<keyword>Mosquito</keyword>
	<keyword>Membrane</keyword>
	<keyword>Feeding</keyword>
	<keyword>Parasites</keyword>
	<keyword>Infection</keyword>
	<keyword>Malaria</keyword>
</DOC>